Responses
Extended reports
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104
Compose a Response to This Article
Other responses
No responses have been published for this article.